期刊
JOURNAL OF RHEUMATOLOGY
卷 40, 期 9, 页码 1523-1528出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.130293
关键词
ARTHRITIS; RHEUMATOID; AUTOANTIBODIES; PEPTIDYLARGININE DEIMINASE
类别
资金
- Canadian Institutes of Health Research [MOP 7770]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [P30AR053503]
- Sibley Memorial Hospital
- NIH [T32 AR048522]
Objective. To determine whether anti-peptidylarginine deiminase type 4 (PAD4) antibodies were present in first-degree relatives (FDR) of patients with rheumatoid arthritis (RA) in 2 indigenous North American populations with high prevalence of RA. Methods. Participants were recruited from 2 indigenous populations in Canada and the United States, including patients with RA (probands), their unaffected FDR, and healthy unrelated controls. Sera were tested for the presence of anti-PAD4 antibodies, anticyclic citrullinated peptide (anti-CCP) antibodies, and rheumatoid factor (RF). HLA-DRB1 subtyping was performed and participants were classified according to number of shared-epitope alleles present. Results. Antibodies to PAD4 were detected in 24 of 82(29.3%) probands; 2 of 147 (1.4%) relatives; and no controls (p < 0.0001). Anti-CCP was present in 39/144 (27.1%) of the relatives, and there was no overlap between positivity for anti-CCP and PAD4 in the relatives. In RA patients, anti-PAD4 antibodies were associated with disease duration (p = 0.0082) and anti-CCP antibodies (p = 0.008), but not smoking or shared-epitope alleles. Conclusion. Despite a significant prevalence of anti-CCP in FUR, anti-PAD4 antibodies were almost exclusively found in established RA. The prevalence of anti-PAD4 antibodies in RA is similar to the prevalence described in other populations and these autoantibodies are associated with disease duration and anti-CCP in RA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据